 BURLINGAME, Calif., Jan. 11, 2021 GLOBE NEWSWIRE -- ALX Oncology Holdings Inc., ALX Oncology Nasdaq: ALXO, a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today provided a corporate update and highlighted key milestones anticipated in 2021. 